Search Results
Aug 26, 2026, 02:46 ET BioArctic: Interim Report for the period April - June 2026
with early Alzheimer's disease. Following the approval, Leqembi Iqlik was launched in the US in AugustData from the LEADER study presented at AAIC (Alzheimer's Association International Conference) in London on July 12–15 showed that more than 75% of patients treated with Leqembi remained stable,
More news about: BioArctic
Aug 26, 2026, 02:43 ET BioArctic: Interim Report for the period April - June 2026
with early Alzheimer's disease. Following the approval, Leqembi Iqlik was launched in the US in AugustData from the LEADER study presented at AAIC (Alzheimer's Association International Conference) in London on July 12–15 showed that more than 75% of patients treated with Leqembi remained stable,
More news about: BioArctic
Jul 23, 2026, 08:30 ET ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
biomarkers continues to be a central theme. The momentum was also evident earlier this month at the Alzheimer's Association International Conference (AAIC), where more than 140 presentations and posters featured data from the NULISAseq CNS Disease 120, Neuro 220, and AD 5-plex panels or NULISAqpcr BD-pTau217
More news about: ALZpath, Inc.
Jul 16, 2026, 03:22 ET Cumulus Neuroscience präsentiert auf der AAIC-Jahrestagung 2026 Daten, die zeigen, dass eine zweiminütige digitale Aufgabe die klinischen Referenzwerte für die Vorauswahl bei Alzheimer-Studien erreicht oder übertrifft
besitzt echtes Potenzial, die Screening-Ausfallraten zu senken sowie die Belastung für Patienten und Studienzentren zu verringern. Die beiden auf der AAIC vorgestellten Poster erzählen eine zusammenhängende Geschichte: Neben dem Potenzial von Symbol Swap für die gezielte Vorauswahl zu Studienbeginn zeigen
More news about: Cumulus Neuroscience
Jul 16, 2026, 00:01 ET RESEARCH ADVANCES FROM THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
alz.org/aaic-for-all.About the Alzheimer's Association International Conference® (AAIC®)The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the
More news about: Alzheimer’s Association
Jul 15, 2026, 09:54 ET Cumulus Neuroscience présente, lors du congrès annuel de l'AAIC 2026, des données montrant qu'une tâche numérique de deux minutes atteint ou dépasse les critères de référence cliniques en matière de pré-sélection des participants à un essai clinique sur la maladie d'Alzheimer.
numérique « Symbol Swap » lors de la Conférence internationale de l'Alzheimer's Association (AAIC) 2026. L'affiche intitulée « Une brève tâche de codage numérique de symboles surpasse les références cliniques pour la présélection des participants
More news about: Cumulus Neuroscience
Jul 15, 2026, 06:00 ET Creyos Cognitive Assessments Featured in Two Studies at AAIC 2026
Alzheimer's Association International Conference (AAIC) 2026, the world's largest scientific meeting dedicated to dementia research. One study uses the Creyos platform to catch cognitive impairment earlier
More news about: Creyos
Jul 15, 2026, 05:11 ET Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
likely to be biomarker-positive, has real potential to cut screen-failure rates and ease the burden on patients and sites. The two posters presented at AAIC tell a connected story: alongside Symbol Swap's power to enrich at the front end, our CNS-101 data show that NeuLogiq's multi-domain cognitive and EEG
More news about: Cumulus Neuroscience
Jul 15, 2026, 05:00 ET Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
likely to be biomarker-positive, has real potential to cut screen-failure rates and ease the burden on patients and sites. The two posters presented at AAIC tell a connected story: alongside Symbol Swap's power to enrich at the front end, our CNS-101 data show that NeuLogiq's multi-domain cognitive and EEG
More news about: Cumulus Neuroscience
Jul 15, 2026, 00:01 ET BLOOD TEST MAY HELP PREDICT RISK OF COGNITIVE DECLINE DUE TO ALZHEIMER'S A DECADE BEFORE SYMPTOMS APPEAR
with scientific advances.About AAICAAIC is the world's largest gathering of researchers from around the world focused on Alzheimer's and other diseases that cause dementia. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge
More news about: Alzheimer’s Association
Jul 14, 2026, 13:56 ET Spinogenix Reports Positive Data on Alzheimer's Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks
two years at 300mg QD and some participants have now completed 84 weeks of treatment.Extended treatment results presented at AAIC 2026: At this year's AAIC meeting, the Phase 2a data were presented alongside new observations on the durability of cognitive improvement over the SAS period in
More news about: Spinogenix
Jul 14, 2026, 11:41 ET More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings" at the Alzheimer's Association International Conference® (AAIC®) 2026 in London. These findings support long-term benefits of continuous treatment with Leqembi and provide important insights into treatment experience
More news about: BioArctic
Jul 14, 2026, 11:39 ET More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings" at the Alzheimer's Association International Conference® (AAIC®) 2026 in London. These findings support long-term benefits of continuous treatment with Leqembi and provide important insights into treatment experience
More news about: BioArctic
Jul 14, 2026, 11:19 ET Diranersen Results at AAIC Provide First Evidence That Targeting Tau May Slow Cognitive Decline, Signaling Momentum Toward Addressing the Full Pathobiology of Alzheimer's
NEW YORK, July 14, 2026 /PRNewswire/ -- Today at the Alzheimer's Association International Conference (AAIC), Biogen presented results from the phase 2 CELIA study of diranersen (BIIB080), an investigational therapy designed to target tau in people with early
More news about: Alzheimer's Drug Discovery Foundation
Jul 14, 2026, 11:15 ET LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings" at the Alzheimer's Association International Conference® (AAIC®) 2026 in London and online.
More news about: Eisai Inc.
Jul 14, 2026, 10:00 ET ImmunoBrain Announces Nature Medicine Publication and Late-Breaking AAIC 2026 Presentation for IBC-Ab002 in Early Alzheimer's Disease
with early Alzheimer's disease. The publication coincides with a late-breaking presentation at the Alzheimer's Association International Conference (AAIC) 2026, highlighting that beyond demonstrating safety, which was the primary endpoint, the study generated encouraging fluid biomarker data, showing
More news about: ImmunoBrain Checkpoint Inc.
Jul 14, 2026, 00:30 ET アルツハイマー病協会国際会議2026（ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2026）より、ライフスタイルプログラムが、ラテンアメリカ全域で認知症リスクのある 高齢者の脳の健康を改善
Conference®（AAIC®）」2026で報告された2年間の研究結果は、米国における以下の研究結果を基盤とし、その知見を裏付けるものです。「リスク低減に向けたライフスタイル介入による脳の健康保護に関する研究（U.S.
More news about: Alzheimer’s Association
Jul 14, 2026, 00:01 ET ALZHEIMER'S BLOOD TEST COULD BRING HIGHLY ACCURATE DIAGNOSIS INTO EVERYDAY CLINICAL CARE
patient at the right time."About AAICAAIC is the world's largest gathering of researchers from around the world focused on Alzheimer's and other diseases that cause dementia. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge
More news about: Alzheimer’s Association
Jul 13, 2026, 19:03 ET ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future
making more personalized treatment strategies possible."New clinical data presented at the Alzheimer's Association International Conference (AAIC) supported that weekly subcutaneous Leqembi performs similarly to the previously approved intravenous (IV) starting regimen, with a generally consistent
More news about: Alzheimer's Drug Discovery Foundation
Jul 13, 2026, 13:44 ET 2026 年阿茲海默症協會國際會議報道
[email protected]關於 AAICAAIC 是全球最大規模的研究會議，匯聚世界各地專注於阿茲海默症及其他認知障礙症的研究人員。作為阿茲海默症協會研究計劃的一環，AAIC 推動認知障礙症新知，也培養蓬勃發展、緊密合作的研究社群。AAIC 2026：
More news about: Alzheimer’s Association
Jul 13, 2026, 08:15 ET Halia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer's Prevention in APOE4 Carriers
July 13, 2026 /PRNewswire/ -- Halia Therapeutics today announced two posters at the Alzheimer's Association International Conference (AAIC) 2026, July 12–15, linking preclinical data on its LRRK2 inhibitor HT-4253 to a biomarker trial to prevent or delay Alzheimer's disease (AD).
More news about: Halia Therapeutics
Jul 13, 2026, 06:00 ET NeuroTherapia to Present Phase 2a Alzheimer's Disease Clinical Data at the AAIC 2026 Conference in London, UK
presenting data from its recently completed Phase 2a clinical trial in Alzheimer's Disease (AD) at the Alzheimer's Association International Conference (AAIC) 2026 during the Monday July 13th poster session. The trial was a 28-day, multicenter, randomized, double-blind, placebo-controlled study
More news about: NeuroTherapia, Inc.
Jul 13, 2026, 05:53 ET 2026 年阿茲海默症協會國際會議：生活方式計劃改善拉丁美洲有失智風險長者的腦部健康
訣竅」。關於 AAICAAIC 是全球規模最大的阿茲海默症及其他導致失智症的疾病研究人員的會議。 作為阿茲海默症協會研究計劃的一環，AAIC 致力於促進對失智症新知識的產生，並培養充滿活力、合作共贏的研究社群。AAIC 2026：
More news about: Alzheimer’s Association
Jul 13, 2026, 05:30 ET INDIANA UNIVERSITY AND PHARMATROPHIX PRESENT FINDINGS ON PERFORMANCE OF ORAL THERAPEUTIC, LM11A-31, TO REDUCE DECLINE OF BRAIN FUNCTIONAL-NETWORK CONNECTIVITY IN ALZHEIMER'S DISEASE
communication networks in people with mild-to-moderate Alzheimer's disease. The analysis was presented at The Alzheimer's Association International Conference (AAIC) in London.
More news about: PharmatrophiX
Jul 13, 2026, 04:53 ET 알츠하이머 협회 국제 콘퍼런스 2026: 라이프스타일 프로그램, 라틴아메리카 전역에서 치매 위험이 있는 노인들의 뇌 건강 개선
레시피'를 제공한다.AAIC 소개AAIC는 알츠하이머와 치매를 유발하는 다른 질병들에 초점을 맞춘 전 세계 연구자들의 세계 최대 모임이다. 알츠하이머 협회 연구 프로그램의 일부로서 AAIC는 치매에 대한 새로운 지식을 생성하고, 활발하고 우호적인 연구 커뮤니티를 조성하는 촉매제 역할을 한다.AAIC 2026:
More news about: Alzheimer’s Association